TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06343311: T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Sponsor: Estrella Immunopharma, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 27 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$1,060,290

Rescue Site Savings

+$706,860

Unlock Full NCT06343311 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06343311 Rescue Dossier →